RU2371198C2 - Улучшенная вспомогательная терапияопухолей, экспрессирующих g250 - Google Patents

Улучшенная вспомогательная терапияопухолей, экспрессирующих g250 Download PDF

Info

Publication number
RU2371198C2
RU2371198C2 RU2007104040/14A RU2007104040A RU2371198C2 RU 2371198 C2 RU2371198 C2 RU 2371198C2 RU 2007104040/14 A RU2007104040/14 A RU 2007104040/14A RU 2007104040 A RU2007104040 A RU 2007104040A RU 2371198 C2 RU2371198 C2 RU 2371198C2
Authority
RU
Russia
Prior art keywords
antibody
antigen
treatment
use according
patients
Prior art date
Application number
RU2007104040/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2007104040A (ru
Inventor
Олаф ВИЛЬХЕЛЬМ (DE)
Олаф ВИЛЬХЕЛЬМ
Свен ВАРНААР (NL)
Свен ВАРНААР
Original Assignee
Вилекс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вилекс Аг filed Critical Вилекс Аг
Publication of RU2007104040A publication Critical patent/RU2007104040A/ru
Application granted granted Critical
Publication of RU2371198C2 publication Critical patent/RU2371198C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2007104040/14A 2004-07-02 2005-06-29 Улучшенная вспомогательная терапияопухолей, экспрессирующих g250 RU2371198C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58467904P 2004-07-02 2004-07-02
US60/584,679 2004-07-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2009122344/15A Division RU2519340C2 (ru) 2004-07-02 2009-06-10 Улучшенная вспомогательная терапия опухолей, экспрессирующих g250

Publications (2)

Publication Number Publication Date
RU2007104040A RU2007104040A (ru) 2008-08-10
RU2371198C2 true RU2371198C2 (ru) 2009-10-27

Family

ID=35431139

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2007104040/14A RU2371198C2 (ru) 2004-07-02 2005-06-29 Улучшенная вспомогательная терапияопухолей, экспрессирующих g250
RU2009122344/15A RU2519340C2 (ru) 2004-07-02 2009-06-10 Улучшенная вспомогательная терапия опухолей, экспрессирующих g250

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2009122344/15A RU2519340C2 (ru) 2004-07-02 2009-06-10 Улучшенная вспомогательная терапия опухолей, экспрессирующих g250

Country Status (13)

Country Link
US (1) US7691375B2 (https=)
EP (2) EP1763367A2 (https=)
JP (1) JP2008505143A (https=)
KR (1) KR101205289B1 (https=)
CN (1) CN101052416B (https=)
AU (1) AU2005259481B2 (https=)
BR (1) BRPI0512854A (https=)
CA (1) CA2566950A1 (https=)
DK (1) DK2497497T3 (https=)
ES (1) ES2641089T3 (https=)
MX (1) MXPA06013240A (https=)
RU (2) RU2371198C2 (https=)
WO (1) WO2006002889A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2442983C1 (ru) * 2011-01-14 2012-02-20 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
KR20120082429A (ko) 2009-09-18 2012-07-23 미쓰비시 가가꾸 가부시키가이샤 간세포암 마커
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
BR112015020061A8 (pt) * 2013-02-22 2018-01-23 Wilex Ag composto alvo anidrase carbônica ix (caix) para tratamento de câncer, seus usos, composição farmcêutica, e método para diagnosticar, prognosticar e/ou classificar um câncer
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008854A1 (en) * 1987-05-06 1988-11-17 Egbert Oosterwijk Monoclonal antibodies to renal cell carcinoma
RU2257200C1 (ru) * 2004-05-12 2005-07-27 Кутушов Михаил Владимирович Лекарственное средство

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
DK1733736T3 (en) * 2001-02-07 2015-06-01 Wilex Ag A process for the production of recombinant antibodies to tumors
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008854A1 (en) * 1987-05-06 1988-11-17 Egbert Oosterwijk Monoclonal antibodies to renal cell carcinoma
RU2257200C1 (ru) * 2004-05-12 2005-07-27 Кутушов Михаил Владимирович Лекарственное средство

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAWATA N. et al Immunological effect of recombinant interferon-gamma in renal cell carcinoma // Hinyokika Kiyo. 1993 Jun; 39(6):511-5. реферат, он-лайн [Найдено в Интернет на www.pubmed.com 20.10.2008], PMID: 8337976 [PubMed - indexed for MEDLINE]. BLEUMER I et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients // Br J Cancer. 2004 Mar 8; 90(5):985-90. реферат, он-лайн [Найдено в Интернет на www.pubmed.com 20.10.2008], PMID: 14997194 [PubMed-indexed for MEDLINE] OOSTERWIJK E. et al. Monoclonal antibody-based therapy for renal cell carcinoma. // Urol Clin North Am. 2003 Aug; 30(3):623-31. реферат, он-лайн [Найдено в Интернет на www.pubmed.com 08.10.2008], PMID: 12953760 [PubMed - indexed for MEDLINE]. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2442983C1 (ru) * 2011-01-14 2012-02-20 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции

Also Published As

Publication number Publication date
CA2566950A1 (en) 2006-01-12
BRPI0512854A (pt) 2008-04-08
EP2497497A1 (en) 2012-09-12
JP2008505143A (ja) 2008-02-21
US20070207157A1 (en) 2007-09-06
EP1763367A2 (en) 2007-03-21
RU2519340C2 (ru) 2014-06-10
EP2497497B1 (en) 2017-06-21
MXPA06013240A (es) 2007-02-28
CN101052416A (zh) 2007-10-10
KR20070036085A (ko) 2007-04-02
AU2005259481A1 (en) 2006-01-12
CN101052416B (zh) 2013-07-10
RU2009122344A (ru) 2010-12-20
US7691375B2 (en) 2010-04-06
ES2641089T3 (es) 2017-11-07
WO2006002889A2 (en) 2006-01-12
DK2497497T3 (en) 2017-08-14
WO2006002889A3 (en) 2006-10-05
RU2007104040A (ru) 2008-08-10
AU2005259481B2 (en) 2010-04-22
KR101205289B1 (ko) 2012-11-27

Similar Documents

Publication Publication Date Title
RU2519340C2 (ru) Улучшенная вспомогательная терапия опухолей, экспрессирующих g250
Chung et al. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma
Griffiths et al. Current perspectives in bladder cancer management
Yamamoto et al. Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021
CN108026173A (zh) 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
Lutt et al. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis
Weber et al. Personalizing locoregional therapy in patients with breast cancer in 2024: tailoring axillary surgery, escalating lymphatic surgery, and implementing evidence-based hypofractionated radiotherapy
Barnabe et al. Successful treatment of cardiac sarcoidosis with infliximab
Lin et al. Immune microenvironment of primary and recurrent craniopharyngiomas: A study of the differences and clinical significance
Herlyn et al. Initial clinical evaluation of two murine IgG2a monoclonal antibodies for immunotherapy of gastrointestinal carcinoma
Kao et al. The impact of preoperative chemoradiotherapy on advanced low rectal cancer
Freedman et al. Solitary late recurrence of renal cell carcinoma presenting as duodenal ulcer
Bao et al. Advanced cholangiocarcinoma with human epidermal growth factor receptor 2 (HER2) amplification treated with Trastuzumab deruxtecan (T-DXd): A case report
Yildirim-Toruner et al. Hodgkin’s lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis
Song et al. Blocking transforming growth factor-beta reduces the migration and invasion of the residual tumour after TAE
Yamamoto et al. Fibrin-associated diffuse large B-cell lymphoma arising in an abdominal aortic graft: A case report and literature review
Ames et al. Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia
Malik et al. Surgically treated rectal cancer patients—Outcomes at a tertiary care cancer hospital in Pakistan
Peleaæã et al. Axillary Reverse Mapping Using Indocyanine Green and Concurrent Sentinel Lymph Node Biopsy in Breast Cancer Patients with or without Neoadjuvant Systemic Treatment
Mahipal et al. Gallbladder Cancer
Ohta et al. Case Report: Severe neutropenia induced by avelumab in a patient with Merkel cell carcinoma
Tiwari et al. Effectiveness of Sorafenib in hepatic hemangioma
Plimack et al. Kidney cancer
House Adjuvant therapy in colorectal cancer
Kast et al. Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-α and be the cause of treatment related new onset disease: the need to measure circulating TNF-α

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190630